Mesothelioma Clinical Trials Involve Gene Therapy

Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen receptor (CAR) T cell therapy, which includes removing T cells from a patient, arming them with a protein linked to a particular cancer and then returning those cells to the patient. CAR T cell therapy already has shown considerable promise with blood cancers such as leukemia, which prompted the FDA’s groundbreaking approval. But its effectiveness with solid tumors, such as mesothelioma, has been limited until recently. Memorial Sloan Kettering Leading the Way Memorial Sloan Kettering has been a worldwide leader in developing CAR T cell therapy for cancer, making it safer and more effective. Adusumilli, who specializes in thoracic cancers, is the chief investigator of a promising clinical trial involving T cells genetically engineered to target mesothelin, a protein found in almost 90 percent of pleural mesothelioma tumors. Early trial results are encourag...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news

Related Links:

"The first doctor who saw me told me to go home and die," says a pancreatic cancer survivor who hopes one day no one else will have to hear those words
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
Authors: Koehler LA, Hunter DW Abstract Axillary web syndrome (AWS) is a frequently overlooked problem that causes morbidity in the early post-operative period following cancer surgery with axillary lymph node removal (1-3). AWS, also known as “cording” was first described in 2001 by Moskovitz as “a visible web of axillary skin overlying palpable cords of tissue that are made taut by shoulder abduction” (1). Over a decade has passed since Moskovitz’s seminal article was published, and we still lack a good understanding of AWS. This condition has been suboptimally studied using widely d...
Source: Lymphology - Category: Internal Medicine Tags: Lymphology Source Type: research
Authors: Skowronski M, Risør MB, Andersen RS, Foss N Abstract Little is known about how people living in the aftermath of cancer treatment experience and manage worries about possible signs of cancer relapse, not as an individual enterprise but as socially embedded management. One-year ethnographic fieldwork was conducted in a coastal village of under 3000 inhabitants in northern Norway. Ten villagers who had undergone cancer treatment from six months to five years earlier were the main informants. During fieldwork, the first author conducted qualitative, semi-structured monthly interviews with them, and par...
Source: Anthropology and Medicine - Category: International Medicine & Public Health Tags: Anthropol Med Source Type: research
Supplementation with Robuvit® in post-mastectomy post-radiation arm lymphedema. Minerva Chir. 2018 Jun;73(3):288-294 Authors: Belcaro G, Dugall M, Cotellese R, Feragalli B, Cianchetti E, Cesarone MR Abstract BACKGROUND: Post-mastectomy lymphedema is one of the most significant, non-life-threatening complications following breast cancer surgery and radiotherapy. Post-mastectomy post-radiotherapy (PMPR) lymphedema is related to damages to lymphatics and/or veins during/after axillary surgery and radiotherapy. The management of this condition is very challenging; the comprehensive decongestive therapy...
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
NEW YORK (CBS Local/CBS News) – Smoking in the U.S. has hit another all-time low. About 14 percent of U.S adults admit to being smokers last year, down from about 16 percent in 2016, government figures from the CDC show. There hadn’t been much change the previous two years, but it’s been clear there’s been a general decline and the new figures show it’s continuing, according to K. Michael Cummings of the tobacco research program at Medical University of South Carolina. “Everything is pointed in the right direction,” including falling cigarette sales and other indicators, Cummi...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Local TV Smoking talkers Source Type: news
The science is clear: Drinking too much alcohol is bad for your health, but exactly how low-risk is light drinking?
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Nat. Prod. Rep., 2018, Advance Article DOI: 10.1039/C8NP00013A, Review ArticleMichael[space]W. Mullowney, Ryan A. McClure, Matthew T. Robey, Neil L. Kelleher, Regan J. Thomson Thioester reductases arm natural products, such as the peptide aldehydes and the anti-cancer drug Yondelis, with unique structures and bioactivity. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Nat. Prod. Rep. latest articles - Category: Chemistry Authors: Source Type: research
Lyft and the American Cancer Society are expanding a partnership that provides free rides to cancer patients to one state and seven cities including Denver. In addition to existing partnerships in Las Vegas and Miami, the program is expanding to the Mile High City as well as Atlanta, Cincinnati, Houston, Los Angeles, Philadelphia and St. Louis as well as the state of New Jersey. When patients contact the ACS for a ride to cancer treatments, the socie ty will be able to use Lyft’s Concierge tool…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Authors: Chen L, Ye Y, Chen H, Chen S, Jiang J, Dan G, Huang B Abstract OBJECTIVE: To study the difference of the Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) parameters among the primary tumor, metastatic node and peripheral normal tissue of head and neck cancer. MATERIALS AND METHODS: Consecutive newly-diagnosed head and neck cancer patients with nodal metastasis between December 2010 and July 2013 were recruited, and 25 patients (8 females; 24~63,mean 43±11 years old) were enrolled. DCE-MRI was performed in the primary tumor region including the regional lymph nodes on a 3.0-T MRI sy...
Source: Current Medical Imaging Reviews - Category: Radiology Tags: Curr Med Imaging Rev Source Type: research
AbstractAttaching a cytotoxic “payload” to an antibody to form an antibody–drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface molecules. The first ADC to receive marketing authorization was gemtuzu mab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia. It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial. The development of...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Asbestosis | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cardiovascular & Thoracic Surgery | Clinical Trials | Conferences | Environmental Health | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Immunotherapy | Laboratory Medicine | Leukemia | Lung Cancer | Mali Health | Mesothelioma | Pediatrics | Study | University of Pennsylvania